Skip to main content
SENATE 1131118th CongressRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Drug Price Transparency Act of 2023

Last Action
3/30/2023

Actions

  • 2023-03-30Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • 2023-03-30Introduced in Senate

CRS Summary

As of 2023-03-30 (00)

Drug Price Transparency Act of 2023

This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws.

Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.

Cosponsors (1)

  • Cindy Hyde-Smith (R-MS)
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.